<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="694">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02150213</url>
  </required_header>
  <id_info>
    <org_study_id>CBGG492A2216</org_study_id>
    <secondary_id>2013-003431-29</secondary_id>
    <nct_id>NCT02150213</nct_id>
  </id_info>
  <brief_title>Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492</brief_title>
  <official_title>A Multicenter Medical Safety Follow-up Study for Patients With Partial Onset Seizures Who Received More Than 28 Days of Total Exposure to BGG492 in Studies CBGG492A2207 and/or CBGG492A2212</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices (BfArM)</authority>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Poland: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To provide medical follow-up to patients exposed to BGG492 for more than 28 days in study
      CBGG492A2207 and/or CBGG492A2212.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to provide medical follow-up to patients exposed to BGG492 for
      more than 28 days in study CBGG492A2207 and/or CBGG492A2212. Data from study CBGG492A2216
      will be used to support the clinical safety assessment of BGG492 regarding the observance of
      uterine endometrial stromal tumors and adrenal cortical adenomas at least one year after the
      completion of BGG492 treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Incidence of adrenal cortical adenomas</measure>
    <time_frame>By approx day 7 or earlier</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of adrenal cortical adenomas as assessed by non-contrast MRI of the abdomen (males and females)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of uterine endometrial stromal sarcomas</measure>
    <time_frame>By approx day 31 or earlier</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of uterine endometrial stromal sarcomas as assessed by sonogram/biopsy (females)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>Monitored for the duration of the study which is approx 42 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence and severity of adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Adrenocortical Adenoma</condition>
  <condition>Sarcoma, Endometrial Stromal</condition>
  <arm_group>
    <arm_group_label>All patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients who get enrolled in the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI of the abdomen</description>
    <arm_group_label>All patients</arm_group_label>
    <other_name>Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dexamethasone Supression Test</intervention_name>
    <description>Dexamethasone Supression test</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sonogram</intervention_name>
    <description>Sonogram of the uterus (females only)</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Uterine endometrial biopsy (females only)</description>
    <arm_group_label>All patients</arm_group_label>
    <other_name>Uterine biopsy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGG492</intervention_name>
    <description>No study-drug gets administered in this study</description>
    <arm_group_label>All patients</arm_group_label>
    <other_name>Selurampanel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Total exposure to BGG492 treatment in study CBGG492A2207 and/or CBGG492A2212 must
             have been greater than 28 days.

          -  At least one year must have elapsed since the patient received his or her last dose
             of BGG492.

        Exclusion Criteria:

        - None

        Other protocol-defined inclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monroe Township</city>
        <state>New Jersey</state>
        <zip>08831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bernau</city>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kehl-Kork</city>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50143</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>110 744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hlohovec</city>
        <state>Slovak Republic</state>
        <zip>92001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <state>Slovak Republic</state>
        <zip>041 90</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97517</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 17, 2015</lastchanged_date>
  <firstreceived_date>May 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenocortical Adenoma</mesh_term>
    <mesh_term>Sarcoma, Endometrial Stromal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
